ERBB2 Rabbit Polyclonal Antibody

CAT#: TA367829

ERBB2 rabbit polyclonal antibody

Product Images

Gel: 6%SDS-PAGE Lysate: 40 μg Lane 1-2: Hela and HUVEC cell lysates Primary antibody: TA367829 (ERBB2 Antibody) at dilution 1/350 Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution Exposure time: 1 minute

• 

  Immunohistochemistry of paraffin-embedded Human lung cancer tissue using TA367829 (ERBB2 Antibody) at dilution 1/35 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human lung cancer tissue using TA367829 (ERBB2 Antibody) at dilution 1/35, treated with synthetic peptide. (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human prostate cancer tissue using TA367829 (ERBB2 Antibody) at dilution 1/35 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human prostate cancer tissue using TA367829 (ERBB2 Antibody) at dilution 1/35, treated with synthetic peptide. (Original magnification: ×200)

Show all 5 images

Specifications

Product Data

• Applications: IHC, WB
• Recommended Dilution: WB: 200-1000
  WB positive control: Hela and HUVEC cell lysates
  IHC: 20-100
  Positive control: Human lung cancer
  Predicted cell location: Cytoplasm and Cell membrane
• Reactivities: Human, Mouse, Rat
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Synthetic peptide of human ERBB2
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Predicted Protein Size: 138 kDa
• Database Link:
  UniProt ID P04626
• Background: The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity. While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members. Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase. ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway.